Qiagen is reportedly assessing strategic options, including a potential sale, according to a Bloomberg report that sent shares higher. The life‑science tools and diagnostics provider has held talks with potential buyers and engaged advisers as its supervisory board evaluates interest from suitors, the report said. Market attention recalls Thermo Fisher’s aborted bid for Qiagen in 2020 and subsequent takeover speculation. Analysts note Qiagen’s diagnostics portfolio and molecular workflows are attractive to both strategic buyers and private equity. Qiagen declined to comment publicly on the report. A completed sale or merger would reshape consolidation among reagent and instrument suppliers and could alter competitive dynamics for molecular diagnostics and sample‑prep solutions.